SCHEMBL1550147

SCHEMBL1550147

O=C(O)N1CCc2c(Br)cccc2C1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABHD6 Q9BV23 7/20 0.60
AKR1C3 P42330 1/20 0.51
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
PRMT1 Q99873 1/20 0.45
TRAP1 Q12931 1/20 0.44
ACACB O00763 3/20 0.44
NOTUM Q6P988 2/20 0.42
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20564523 0.87 ABHD6 (0.60) ABHD6AKR1C3CARM1TRAP1NOTUM
SCHEMBL4008584 0.86 NOTUM (0.61) ABHD6AKR1C3CARM1PRMT6PRMT1
SCHEMBL29644341 0.85 ABHD6 (0.55) ABHD6AKR1C3TRAP1NPC1RAB9A
SCHEMBL28739037 0.85 ABHD6 (0.55) ABHD6AKR1C3TRAP1NPC1RAB9A
SCHEMBL4437645 0.85 ABHD6 (0.57) ABHD6AKR1C3CARM1PRMT6PRMT1
SCHEMBL2804587 0.82 AKR1C3 (0.50) ABHD6AKR1C3TRAP1NOTUMMEN1
SCHEMBL22461027 0.82 ABHD6 (0.55) ABHD6AKR1C3MEN1MAPTKMT2A
SCHEMBL16269157 0.82 ABHD6 (0.55) ABHD6AKR1C3CARM1PRMT6PRMT1
SCHEMBL30159903 0.82 ABHD6 (0.55) ABHD6AKR1C3MEN1MAPTKMT2A
SCHEMBL772680 0.82 ABHD6 (0.69) ABHD6AKR1C3CARM1PRMT6PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2978751-B1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-12-05 EP disclosed
EP-3209652-A1 TRICYCLIC ATROPISOMER COMPOUNDS Bristol-Myers Squibb Company (US) 2017-08-30 EP disclosed
US-9738655-B2 Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-22 US disclosed
US-20160145263-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2016-05-26 US disclosed
EP-2766347-B1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-05-04 EP disclosed
EP-2978751-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2016-02-03 EP disclosed
US-9079929-B2 Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-07-14 US disclosed
WO-2014160668-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-10-02 WO disclosed
US-20140274960-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2014-09-18 US disclosed
EP-2766347-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2014-08-20 EP disclosed
WO-2013056034-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-18 WO disclosed
CN-102076686-B Diketopiperidine derivatives as HIV attachment inhibitors BRISTOL MYERS SQUIBB CO 2013-03-06 CN disclosed
CN-102076686-A Diketopiperidine derivatives as HIV attachment inhibitors BRISTOL MYERS SQUIBB CO 2011-05-25 CN disclosed
EP-2313408-A1 DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS Bristol-Myers Squibb Company (US) 2011-04-27 EP disclosed
WO-2009158396-A1 DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140274960-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS TFPI, TFPI2, KLKB1 ABHD6 4726/4885AKR1C3 323/4885CARM1 4268/4885
US-20160145263-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS TFPI2, TFPI, F12 ABHD6 4879/4885AKR1C3 273/4885CARM1 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.